3.37MMarket Cap-0.18P/E (TTM)
2.7800High2.5300Low8.45KVolume2.6900Open2.6300Pre Close22.29KTurnover0.93%Turnover RatioLossP/E (Static)1.27MShares9.250052wk High0.19P/B2.42MFloat Cap2.370052wk Low--Dividend TTM908.92KShs Float170.0000Historical High--Div YieldTTM9.51%Amplitude2.3700Historical Low2.6370Avg Price1Lot Size
Pasithea Therapeutics Stock Forum
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
54 seconds ago, 4:02 AM PST
Via GlobeNewswire
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule --
-- No dose-limiting toxicities (DLTs) observed to date --
-- No rash observed to date --
📊⚡️📊
Pasithea Therapeutics Announces $5 Million Private Placement Priced at-the-Market Under Nasdaq Rules
No comment yet